Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K)

Resistance remains the major clinical challenge for the therapy of Philadelphia chromosome–positive (Ph+) leukemia. With the exception of ponatinib, all approved tyrosine kinase inhibitors (TKIs) are unable to inhibit the common “gatekeeper” mutation T315I. Here we investigated the therapeutic poten...

Descripción completa

Detalles Bibliográficos
Autores principales: Mian, Afsar Ali, Haberbosch, Isabella, Khamaisie, Hazem, Agbarya, Abed, Pietsch, Larissa, Eshel, Elizabeh, Najib, Dally, Chiriches, Claudia, Ottmann, Oliver Gerhard, Hantschel, Oliver, Biondi, Ricardo M., Ruthardt, Martin, Mahajna, Jamal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285356/
https://www.ncbi.nlm.nih.gov/pubmed/34110462
http://dx.doi.org/10.1007/s00277-020-04357-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285356/
https://www.ncbi.nlm.nih.gov/pubmed/34110462
http://dx.doi.org/10.1007/s00277-020-04357-z

Ejemplares similares